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Abstract
Background: Holotranscobalamin, cobalamin-saturated transcobalamin, is the minor fraction of
circulating cobalamin (vitamin B12), which is available for cellular uptake and hence is physiologically
relevant. Currently, no method allows simple, direct quantification of holotranscobalamin. We now report
on the identification and characterization of a monoclonal antibody with a unique specificity for
holotranscobalamin.
Methods: The specificity and affinity of the monoclonal antibodies were determined using surface
plasmon resonance and recombinant transcobalamin as well as by immobilizing the antibodies on magnetic
microspheres and using native transcobalamin in serum. The epitope of the holotranscobalamin specific
antibody was identified using phage display and comparison to a de novo generated three-dimensional
model of transcobalamin using the program Rosetta. A direct assay for holotrnscobalamin in the ELISA
format was developed using the specific antibody and compared to the commercial assay HoloTC RIA.
Results: An antibody exhibiting >100-fold specificity for holotranscobalamin over apotranscobalamin was
identified. The affinity but not the specificity varied inversely with ionic strength and pH, indicating
importance of electrostatic interactions. The epitope was discontinuous and epitope mapping of the
antibody by phage display identified two similar motifs with no direct sequence similarity to
transcobalamin. A comparison of the motifs with a de novo generated three-dimensional model of
transcobalamin identified two structures in the N-terminal part of transcobalamin that resembled the
motif. Using this antibody an ELISA based prototype assay was developed and compared to the only
available commercial assay for measuring holotranscobalamin, HoloTC RIA.
Conclusion: The identified antibody possesses a unique specificity for holotranscobalamin and can be
used to develop a direct assay for the quantification of holotranscobalamin.
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The clinical consequences of vitamin B12 (cobalamin;
Cbl) deficiency include megaloblastic anemia and pro-
gressive neurologic disease of the central and peripheral
nervous systems. The elderly population is especially
prone to this deficiency because of reduced dietary intake
and impaired absorption of the vitamin [1]. Elevated
homocysteine (HCY) and methylmalonate (MMA) in
blood are a direct consequence of B12 deficiency and
these metabolites have been implicated in vascular dam-
age and neurotoxicity, respectively [2,3].
Cbl in serum is bound to two proteins, transcobalamin
(TC) and haptocorrin (HC). Most of the Cbl in blood is
bound to HC, a purported scavenger protein and a trans-
porter for mobilization of hepatic stores of Cbl, though,
the exact function of HC remains unknown [4]. Approxi-
mately 10–30% of the TC in the blood is saturated with
Cbl (holotranscobalamin, holoTC). TC carries the vita-
min from its site of absorption to the tissues [5] and deliv-
ers the vitamin to cells via a specific receptor with high
affinity for holoTC [6].
Measurement of Total Cbl in serum has been for a long
time the gold standard for evaluating the Cbl status of
patients. However, it is now evident that total serum Cbl
is a rather poor indicator of Cbl status because elevated
HCY and MMA, (indicators of intracellular Cbl defi-
ciency) can coexist with normal serum Cbl levels [7]. It
has been suggested that direct determination of holoTC
may provide a better indicator of Cbl status because it
reflects daily Cbl absorbed and the fraction that is availa-
ble for cellular uptake [8,9]. Although this hypothesis was
originally suggested some 17 years ago [10], reliable and
sensitive methods for measurement of holoTC became
available only recently [11,12]. These methods are man-
ual and thus not suitable for handling the large number of
samples required in the clinical laboratory. In this report,
we describe the identification and characterization of a
mouse monoclonal antibody (mAb) with high specificity
for human holoTC and its usefulness in an ELISA based
prototype assay for holoTC in serum.
Methods
Encapsulated magnetic microspheres (EM1 100/40; mean
diameter, 0.86 µm) coated covalently with goat anti-
mouse IgG (H+L) antibody were from Merck-Eurolab SAS
(France). 57Co labeled cyanoCbl was from MP Biomedi-
cals (UK). Unlabeled cyanoCbl was from Sigma (Nor-
way). Rabbit anti-mouse Fc-γ used for immobilization of
murine mAbs on a SPR sensor chip was from Biacore AB
(Sweden). The production of mouse anti-human TC
mAbs [13], human TC [14], and the synthesis of biotin-
Cbl conjugate [15] have been described previously. The
phagmid-displayed random peptide libraries (two linear
14-mer and one disulfide constrained 9-mer peptide
library) were from Cosmix GmbH, Germany.
SPR studies
Surface plasmon resonance measures in real time the
changes in mass bound to a sensor chip. It detects the
changes in refractive index of the surface layer of a solu-
tion in contact with the sensor chip that are caused by a
variation of the mass on the sensor chip surface. SPR bind-
ing was performed using a Biacore instrument (Biacore
AB) according to the recommendations of the manufac-
turer.
Protocol 1
Rabbit anti-(mouse Fc-γ) IgG (30 mg /L) was immobilized
on the surface of the carbodiimide-activated sensor chip.
The reaction was performed in 50 mmol/L acetate buffer,
pH 5.0 at a flow rate of 5 µL/min, until the SPR signal
reached ~2000 resonance units over baseline. Unreacted
groups were blocked using 1 mol/L ethanolamine, and
the primary antibody, mouse anti-(human TC) IgG, 10
mg/L, was captured on the sensor chip in Hepes-buffered
saline, pH 7.3, 3.4 mmol/L EDTA, 50 mg/L SPR surfactant
(HBS-EP). Mouse serum (1:10 dilution) was then injected
in order to saturate the excessive binding sites on the anti-
(mouse epitope) IgG sensor chip.
Interaction of recombinant apo- or holoTC with the anti-
bodies on the sensor chip was evaluated at TC = 1 nmol/
L to 10 µmol/L, flow 5 µL/min. The Ag/mAb complex was
dissociated by washing with 10 mmol/L HCl after each
analysis. The covalently immobilized rabbit anti-(mouse
Fc-γ) IgG was stable and there was no significant decrease
in the ligand binding during repeated washing and reuse
of the sensor chip. Data points were collected, and the rate
constants for association and dissociation (kon and koff)
were calculated. The equilibrium dissociation corre-
sponded to KD = koff/kon. In some experiments antibody
3–11 was substituted for the rabbit anti-(mouse Fc-γ) IgG
as primary immobilized antibody.
In experiments with binding of phagemid-displayed pep-
tides to antibodies, the phagemids were diluted in HBS-EP
to 1.6 1012 cfu per mL, equaling a peptide concentration
of about 3 nmol/L, and reacted with the immobilized
antibody at a flow rate of 10 µL/min. After each run the
sensor chip was regenerated with 200 mmol/L glycine, pH
2.2. In competition experiments between holoTC and
phage-displayed peptides for binding to mAb 3C4, hol-
oTC was used at 1 µmol/L.
Protocol 2
Biotin-Cbl (100 µmol/L) was immobilized on a streptavi-
din (SA) sensor chip. The immobilized Cbl was saturated
with apoTC (1 µmol/L) forming bound holoTC and mAbPage 2 of 11
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strength was injected. The proteins were stripped from the
SA sensor chip with 200 mmol/L glycine, pH 2.2 prior to
reuse.
Panning of phagemid-displayed random peptide libraries 
with mAb 3C4
MAb 3C4 (40 g/L) was immobilized on paramagnetic
beads (10 g/L). The reaction was performed in 10 mmol/
L acetate buffer, pH 4.0 for 45 min at ambient tempera-
ture. Unreacted groups were blocked using 1 mol/L eth-
anolamine. After washing, 20 µL of beads were mixed
with about 1012 packaged phagemids from each library
and incubated for 1 h. Uncoated carboxybeads were used
as a control. After incubation, beads were washed with
PBS containing 0.05% Tween 20. Bound phagemids were
eluted with 200 mmol/L glycine buffer, pH 2.2 and imme-
diately neutralized with 1 mol/L Tris, pH 8.0. Amplifica-
tion and purification and selection of specific phagemid
peptides was performed using standard protocols. In
brief, ELISA wells were coated with mAb 3C4 (100 ng/
well) or unrelated antibody over night at 4°C and then
blocked with 10 mg/mL BSA in PBS (PBA) for 1 h at RT.
Centrifuged packaged phagemids were added at a concen-
tration of 1010 to 108 cfu per well in PBS and incubated for
1 h. Wells were washed 5 times with PBS containing 0.1%
Tween-20 and 3 times with PBS. Bound phage particles
Binding of holoTC and apoTC by anti-human TC mAbsF gure 1
Binding of holoTC and apoTC by anti-human TC mAbs. (A) SPR sensorgram of the binding of mAb 3C4 to immobi-
lized recombinant holoTC and apoTC. HoloTC and apoTC were first bound to mAb 3–11, which was covalently attached to 
the sensor chip, and then mAb 3C4 was injected over the sensor chip. (B) The affinity and specificity of seven different antibod-
ies for native holoTC and apoTC. The Figure depicts one experiment using quadruplicate assays. Antibodies were immobilized 
on paramagnetic microspheres. See Material and Methods. (C) Binding of 57Cbl holoTC to mAb 3C4 and mAb 3–9 as a func-
tion of pH. (D) Binding of 57Cbl holoTC to mAb 3C4 and mAb 3–9 as a function of ionic strength at pH 7.3.Page 3 of 11
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in PBS.
Binding of 57Co-cobalamin labeled TC to anti-human TC 
monoclonal antibodies
Monoclonal anti-TC IgG were bound to polyclonal goat
anti-(mouse epitope) IgG that were covalently linked to
magnetic microspheres as described previously [11]. TC in
1.8 mL of human serum was labeled with 57Cbl (300
pmol/L, 30 min). A 90 µL aliquot of the radiolabeled
serum was incubated with 10 µL of each anti-TC IgG
coated microsphere preparation at room temperature for
1 h, the microspheres were separated using a magnet, and
the radioactivity in each fraction was determined. An
equivalent amount of 57Cbl in PBA was used to determine
non-specific binding.
To assess the binding of native apoTC, a 90 µL aliquot of
unlabeled serum was incubated with 10 µL of each anti-
TC IgG coated microsphere preparation at room tempera-
ture for 1 h. Microspheres and supernatant were separated
using a magnet. ApoTC bound to the microspheres was
labeled with 57Cbl in 100 µL PBA (300 pmol/L, 30 min),
separated using a magnet, and the radioactivity measured.
ApoTC remaining in the supernatant was determined by
labeling with 57Cbl (300 pmol/L, 30 min) and incubating
for 1 h with 15 µL mAb 3–9 coated microspheres, suffi-
cient to bind all TC in the sample. Microspheres were sep-
arated using a magnet and the bound radioactivity
determined.
Conjugation of antibody 3–11 with HRP
Monoclonal antibody 3–11 was coupled to horse-radish
peroxidase (HRP) using Ez-link™ Maleimide Activated
HRP kit (Pierce, USA) and a protocol supplied by the
manufacturer. In short, mAb 3–11 in PBS was modified
with a 25-fold molar excess of N-succinimidyl S-acetylth-
ioacetate in dimethylformamide and after 30 min, depro-
tected with a 90-fold molar excess of hydroxylamine for 2
h at ambient temperaure. The thiolated antibody was
desalted and then reacted with an eight-fold excess of EZ-
Link™ Maleimide Activated HRP at ambient temperature
for 1 h and dialyzed three times against 100 volumes of
PBS.
Non-isotopic sandwich assay for holoTC using mAb 3C4 as 
capture antibody
Maxisorb plates (NUNC-Immuno™, Denmark) were
coated with 10 µg/mL mAb 3C4 in PBS over night at 4°C
and then blocked with PBA for 2 h at ambient tempera-
Table 2: Dependence of binding kinetics on pH and ionic strength as measured by SPR
Immobilized 
reagent
pH NaCl (mmol/L) kon (104 M-1s-1) koff (10-4 s-1) KD (nmol/L)
HoloTC 6.0 0 10 1 1
7.4 0 8 0.4 0.5
7.4 300 7 0.6 0.9
8.0 0 7 0.2 0.3
MAb 3C4 6.0 0 50 4 0.8
6.0 300 0.3 35 1340
7.4 0 3 14 46
7.4 300 0.3 41 1380
8.0 0 7 19 27
Table 1: Binding kinetics for anti-human TC mAbs as measured by SPR
MAb Isotype Epitope1 KD2 (nmol/L) Holo/apo specificity (-
fold)
3–9 IgG1 1 0.03 1
3–11 IgG2a 2a 0.2 1
TC7 IgG2a 2a 10 1
4–7 IgG2b 2b 0.5 3
5H2 IgG1 2b >100 4
TC4 IgG1 3 5–10 1
TC2 IgG1 4 1 1
3C12 IgG1 5 5 1
3C4 IgG1 6 none >100
1 Epitope nomenclature follows that given in ref. 15. Mab 3C4 was originally assigned the same epitope as TC2 (epitope 4). Based on additional data, 
it has been reassigned a new epitope 6.
2 Approximate KD values for apoTC.Page 4 of 11
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well and incubated at ambient temperature for 30 min.
After washing three times with 200 µL of PBA containing
0.05% Tween 20 (wash buffer), 100 µL of HRP-conju-
gated mAb 3–11 was added and the mixture was incu-
bated for 30 min at ambient temperature. Each well was
washed three times in wash buffer and 100 µL of the HRP-
substrate, TMB (BioFx inc., USA) was added and incu-
bated for 10 min. The reaction was quenched with 100 µL
0.12 mol/L HCl and the color developed was measured at
a wavelength of 450 nm.
To produce a calibration curve, 10 mL of serum was
treated with an excess of the high affinity mAb 3–9 immo-
bilized onto magnetic microspheres, so as to remove all
TC in the sample. Another 10 mL of the same serum was
saturated with cyanoCbl. The individual calibrators were
then constructed by mixing the two serum pools in differ-
ent ratios, giving values from 390 to 7 pmol/L of holoTC.
HoloTC values were determined using the commercially
available holoTC assay kit HoloTC RIA (Axis-Shield, Nor-
way).
Results
SPR analysis
The binding properties and epitope specificity of 9 mAbs
were determined by SPR measurements in a Biacore
instrument. Recombinant apoTC or holoTC was immobi-
lized on the chip via the first mAb attached to rabbit anti-
(mouse epitope) IgG, whereupon the second mAb was
injected. All mAbs were combined in all possible permu-
tations. This analysis identified one antibody, 3C4 that
did not bind apoTC (Fig. 1A). The specificity of mAb 3C4
for holoTC was at least 100-fold higher than for apoTC
(Table 1). From the sensorgams a KD = 75 nmol/L was
determined for the binding of mAb 3C4 to holoTC. Two
other antibodies, 5H2 and 4–7 (epitope cluster 2) exhib-
ited weak preference for holoTC over apoTC (Table 1).
The remaining mAbs recognized different epitopes but
reacted equally with both apoTC and holoTC. Our previ-
ous studies [15] had indicated that mAbs TC2 and 3C4
bound to the same epitope cluster 4 because binding of
one mAb completely blocked the binding of the other
mAb. However, the current experiments showed a clear
difference in the ability of the two mAbs to interact with
apoTC and holoTC. Therefore, mAb 3C4 has been reas-
signed to a new epitope 6. The specificity of mAb 3C4 for
holoTC suggested that the bound Cbl may be an integral
part of the corresponding epitope. To investigate this,
mAb 3C4 was injected over a streptavidin sensor chip
coated with biotin-Cbl [15]. No binding of mAb 3C4
directly to the immobilized Cbl was observed. Likewise, a
15-fold molar excess of cyanoCbl did not inhibit the bind-
ing of mAb 3C4 to immobilized holoTC.
Evaluation of holoTC specificity for mAb 3C4 immobilized 
on magnetic microspheres
The specificity of mAb 3C4 was further investigated using
native TC in serum. To determine binding of apoTC, mAb-
coated microspheres were incubated with untreated
serum, and to determine binding of holoTC they were
incubated with serum containing 57Cbl-labeled holoTC
(see Experimental Procedures). The results corroborated
those seen in the SPR experiments (Fig. 1A, 1B). MAb 3C4
bound holoTC but showed no significant binding of
apoTC. The specificity of 3C4 for holoTC was at least 70-
fold higher than for apoTC.
Factors influencing the binding characteristics
The binding of 57Cbl labeled holoTC by mAb 3C4 immo-
bilized on magnetic beads was affected by pH and ionic
strength. Binding increased at lower pH, reaching a pla-
teau at about pH 6.1, the pI for TC (Fig. 1C), and
decreased with increasing ionic strength. (Fig 1D). Alter-
ing pH or ionic strength did not affect the specificity, and
apoTC was not bound above background level at any pH
or ionic strength tested. Other anti-human TC antibodies
(mAbs 3–11 and 3–9) were not significantly affected by
either variable. There was no significant difference
between different anions (Cl, SCN, SO4) or cations (Na,
K, Mg, Ca) (data not shown). SPR data indicated that
although both on and off-rates were affected by pH and
ionic strength the effect on the on-rate was predominant
when holoTC bound immobilized mAb 3C4 (Table 2).
When holoTC was immobilized on the sensor chip and
mAb 3C4 was eluted over it, pH and ionic strength effects
largely disappeared. Presence or absence of 3 mM EDTA
had no effect.
Epitope mapping of mAb 3C4 using phage-displayed 
peptide libraries
Previous results had shown that mAb 3C4 bound only
native holoTC, whereas neither reduced TC nor fragments
of TC were recognized by mAb 3C4 [15]. This observation
together with the failure of mAb 3C4 to bind apoTC or
Cbl indicated that the epitope of mAb 3C4 is discontinu-
ous with the relevant residues dissipated along the amino
acid sequence and brought into close proximity only after
binding of Cbl. To elucidate this further, we used phage
display to map mAb 3C4, as this technique is often suc-
cessful in identifying both continuous and discontinuous
epitopes [16]. Three phage-displayed random peptide
libraries were screened with mAb 3C4, two linear 14-mer
libraries and one disulfide constrained 9-mer library. The
mAb did not react with any specific peptides in the two
linear peptide libraries, suggesting the absence of any con-
tinuous epitope. In contrast, the constrained peptide
library, which has a greater probability of identifying dis-
continuous epitopes, generated a series of specific phago-
topes forming two similar motifs (Table 3). ThesePage 5 of 11
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in human TC, which is in agreement with a discontinuous
epitope. A comparison of the phagotopes with an in silico
generated model of TC [15] identified two structures in
the N-terminal part of TC that resembled the motif. Both
structures have the main sequence in common. One struc-
ture is composed of the anti-parallel sequences
P40WMDRL45 + I54Y55 and is a predicted solvent exposed
loop (Fig. 2). The other structure is composed of the par-
allel sequences P40WMDRL45 + Y72 LHS75. The binding
motif therefore represents a mimotope of the true epitope
on holoTC.
The phagemid displayed peptides were specific for mAb
3C4 (Table 4). Phagemids CS1-6p, CS1-11p, and CS1-31p
were investigated for binding to five other anti-human TC
mAbs (3–9, 5H2, TC4, TC2, and 3C12) that recognized
five different epitopes on TC. Whereas the three
phagemid-displayed peptides bound to immobilized
mAb 3C4 with 24, 32, and 42 RU, respectively, no binding
was observed to the other five mAb (0 RU). The SPR sig-
nals were rather low, but phages do not cause strong SPR
signals for reasons that are thought to depend on the large
size of the phage itself [17]. The interaction between
phagemids and mAb 3C4 was inhibited in a dose depend-
ent manner by holoTC with IC50 values between 0.2 and
0.4 µmol/L (Table 4). These values are in good agreement
with the KD values estimated from the sensorgrams, which
were 75 nmol/L for the binding of holoTC to mAb 3C4
and about 1 nmol/L for the binding of mAb 3C4 to the
different phagotopes. According to the Cheng-Prusoff
equation, IC50 = KI (1 + S/KD) [18] and assuming that for
holoTC KD ≈ KI, holoTC would inhibit 3 nmol/L of phago-
tope with an IC50 ≈ 0.3 µmol/L. Although the peptides
when bound to the phagemid were specific, chemically
synthesized peptides did not inhibit the binding of 3C4 to
either holoTC or the same peptides bound to phagemid,
demonstrating the importance of mimotope presentation
for its activity.
Non-isotopic sandwich assays for holoTC
Three different assay formats were investigated, using
mAb 3C4 as the capture or the detecting ligand, and meas-
urement of holoTC or the Cbl saturation ratio of TC. (Fig.
3).
MAb 3C4 as capture ligand
The assay protocol is described in Experimental Proce-
dures. Different concentrations of recombinant human
holoTC were added to wells coated with mAb 3C4 and
bound holoTC was detected using mAb 3–11 conjugated
to HRP (Fig. 3A). A typical calibration curve is depicted in
Fig. 4A. Fifteen serum samples with holoTC values rang-
ing from 14 to 139 pmol/L, as determined by HoloTC RIA
[11], were quantified by 3C4 capture assay. A comparison
of the two methods showed good correlation; Y = 0.78X-
0.40, r = 0.96 (Fig 4B).
MAb 3C4 as detecting ligand
This was investigated in the Biacore. Mixtures of apoTC
and holoTC were captured on immobilized mAb 3–11.
The amount of holoTC bound was detected by a fixed
concentration of mAb 3C4 (Fig. 3B). The calibration curve
obtained fitted a one-phase binding hyperbole, Y =
1993X/(178-X); r2 = 1.00 (Fig. 4C). As the serum level of
holoTC is too low for measurement in the Biacore, no
comparison could be made with the HoloTC RIA method.
The mAb 3C4 phagotope CS1-9p and the location of the corresponding utative epitope P40 – Y55 in the simulated thr -dimensional model of TCFigure 2
The mAb 3C4 phagotope CS1-9p and the location of 
the corresponding putative epitope P40 – Y55 in the 
simulated three-dimensional model of TC. (epitope 6, 
red). The epitope clusters identified in [15] are also shown. 
Epitope clusters 1 (pink), 2 (orange), 3 (magenta), 4 (green), 
5 (yellow), and heparin-binding site (blue). The putative 
cobalamin-binding region is also indicated.
Table 3: Phagotope sequences specific for mAb 3C4. Phagotopes 
were identified from a phage-displayed disulfide constrained 9-
mer random peptide library.
Motif 1 CS-x1-x2-Y-x3-W-D-x4-x5-x6-CS
x1 = F, G, L
x2 = F, L, R
x3 = L, P, Q
x4 = M, Q, Y
x5 = D, F
x6 = M, R
Motif 2 CS-F-F-Y-S-L-C-Y-C-W-CSPage 6 of 11
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It has been suggested that the cobalamin saturation ratio
of TC (holoTC:total TC) provides a better index of vitamin
B12 deficiency than the absolute holoTC values [9].
Therefore we investigated such a format in the Biacore.
Different mixtures of apoTC and holoTC were captured
on immobilized mAb 3–11. The amount of holoTC
bound was detected by a fixed concentration of mAb 3C4
and the total amount of TC by mAb 3C12 (Fig. 3C). As
mAb 3C4 is specific for holoTC whereas mAb 3C12 does
not discriminate between the holo and the apo-form, and
the two antibodies do not overlap (15), the saturation
ratio could be determined. The calibration curve obtained
fitted a one-phase binding hyperbole, Y = 0.40X/(0.58-X);
r2 = 1.00 (Fig. 4D).
Discussion
We have previously determined the epitope specificity of
a panel of 17 monoclonal antibodies and their relation to
Cbl and receptor binding regions in TC [15]. In the
present work our aim was to identify epitopes that are
unique to the holo protein, with the over-all objective to
develop an assay for the direct determination of holoTC in
plasma. Since this fraction of TC represents newly
absorbed and circulating Cbl available for cellular uptake,
the quantitative estimation of this fraction may provide a
more accurate measure of physiological Cbl status than
the currently used total serum Cbl status.
The 9 mAbs used in the present work represented all 5
epitope clusters previously identified using holoTC [15].
We obtained an identical epitope map using apoTC, with
one exception, mAb 3C4 did not bind to apoTC. MAb 3C4
was highly specific for holoTC, and no binding of apoTC
above the background level was observed in either SPR
experiments or with labeled serum and antibodies immo-
bilized onto magnetic beads. Such high specificity for the
holo-form may be achieved by an epitope that either
encompasses the cobalamin moiety or is induced by the
binding of cobalamin, i.e. cryptic continuous or discon-
tinuous epitopes. However, the inability of mAb 3C4 to
bind to immobilized cobalamin and of cobalamin to
interfere with the binding of mAb 3C4 to immobilized
holoTC make it highly unlikely that Cbl is a part of the
epitope. Continuous or linear epitopes contain 4–8
amino acids next to each other in the primary sequence
and are usually recognized by the antibody in both native
and denatured protein. The presence of a continuous
epitope in holoTC was considered unlikely for the follow-
ing reasons: mAb 3C4 did not bind to (i) apoTC, which,
apart from lack of Cbl, is only conformationally different
from holoTC, (ii) reduced TC or (iii) fragments of TC. Dis-
continuous epitopes, which consist of amino acids sepa-
rated in the primary sequence but brought together in the
native protein, may be successfully mapped by using
phage-displayed random peptide libraries [16]. We
screened three peptide libraries, two linear 14-mer librar-
ies and one disulfide constrained 9-mer library. Whereas
the two former yielded no specific sequences, a finding in
agreement with a discontinuous epitope for 3C4, the con-
strained library generated a series of specific phagotopes
forming one or possibly two similar motifs. The phago-
topes were true mimics of the epitope since they did not
bind other TC specific antibodies and the binding to mAb
3C4 was inhibited by holoTC. Such mimics of epitopes,
mimotopes may or may not show similarities with the
epitope at the amino acid level. We have, as previously
reported [15], generated a computer based three-dimen-
sional model of apoTC using the de novo modeling pro-
cedures on the automated protein modeling server
HMMSTR/Rosetta [19]. In the absence of any homolo-
gous structures, the accuracy of the model cannot be vali-
dated, and we have used it for visualization purposes.
However, these models often have a higher degree of accu-
racy at the local structural level [20], and this applies in
particular to the Rosetta method, which ranks as the best
3D predicting program available [21]. Therefore, we
investigated the model for structures homologous to the
identified motif. As the model is of apoTC to which mAb
3C4 does not bind we would not expect to find any strik-
ing similarity. However, based on the sequences of the
reactive phage inserts two epitope motifs in the N-termi-
nal part of TC could be inferred from the molecular model
of apoTC. The two epitope motifs have their main
sequence, P40W41M42D43R44, in common. This is associ-
ated with either I54Y55, which is localized in the same pre-
dicted solvent-exposed loop as the main sequence, or with
Y72L73H74S75, which is part of an adjacent parallel alpha-
Table 4: Binding of phagemids to mAb 3C4 and blocking by holoTC.
Phagemid No. of clones Sequence Phage bound (RU) HoloTC IC50 (µM)
CS1-2p 1 csLFYLWDQDRcs 4 -
CS1-6p 10 csFRYLWDQDRcs 24 0.4
CS1-9p 10 csGLYPWDMFRcs 35 0.3
CS1-11p 10 csFRYQWDMFRcs 32 0.2
CS1-29p 1 csFFYSLCYCWcs 20 0.3
CS1-31p 2 csGLYPWDYFMcs 42 0.3
CS1-37p 1 csARYSWDRLRcs 0 -Page 7 of 11
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YLHS) are localized on the opposite side of TC relative to
epitope clusters 1, 2, and 3. This is in agreement with pre-
vious results indicating that the epitope of mAb TC2
(epitope 4), which is mutually exclusive with 3C4 on hol-
oTC, is on the opposite side of the TC molecule compared
to the epitope clusters 1, 2, and 3 [15]. The epitopes of
antibodies TC2 and 3C4 are not in close proximity in the
primary sequence. However, it is known that TC and the
closely related Cbl-transporting protein, intrinsic factor,
change their conformation when binding Cbl, which
results in a reduced Stokes radius [22]. In addition, it was
recently demonstrated that Cbl assembles distant
domains of intrinsic factor in a more compact structure
with high affinity for Cbl and its specific receptor [23,24].
It seems reasonable to assume that a similar transforma-
tion occurs in TC in view of the 28-fold higher affinity of
holoTC for the receptor compared to apoTC [5]. In line
with this assumption, the epitopes of mAb TC2 (epitope
4) and mAb 3C4 (epitope 6) are quite close in the 3D
model of TC (Fig. 4). We conclude that mAb 3C4 binds to
a discontinuous epitope existing only in holoTC and ten-
tatively localize it to the loop P40W41M42D43R44-X9-I54Y55
or the parallel alpha-helixes P40W41M42D43R44 and
Y72L73H74S75 in holoTC (Fig. 2). MAb 3C4 has been previ-
ously assigned to epitope cluster 4 because it is mutually
exclusive with mAb TC2 on holoTC [15]. Based on the
new finding that mAb 3C4 does not recognize apoTC, it
has been reassigned to the new epitope 6. Likewise, mabs
5H2 and 4–7, but not mAbs TC7 and 3–11, all binding to
epitope cluster 2, display preferential binding to holoTC
over apoTC (Table 1). Therefore epitope cluster 2 has been
Three different assay formats for the direct measurement of holoTCFigure 3
Three different assay formats for the direct measurement of holoTC. (see main text for details). (A) MAb 3C4 as 
capture ligand for holoTC and mAb 3–11 as detecting ligand. (B) MAb 3–11 as capture ligand for total TC and mAb 3C4 as 
detecting ligand for holoTC. (C) MAb 3–11 as capture ligand for total TC and mAb 3C4 as detecting ligand for holoTC and 
mAb 3C12 as detecting ligand for total TC.Page 8 of 11
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clusters and the putative binding site for Cbl inferred from
the findings that (i) the conserved region S192 – L206 is
important for Cbl binding [25], (ii) the C-terminal
domain A320 – W427 is involved in Cbl binding, albeit
weakly [15], and (iii) mAb 3–9 (epitope cluster 1) sup-
presses Cbl binding to TC [13]. As indicated in Fig. 2, the
holoTC specific region is thus localized far away from the
Cbl-binding region.
The affinities of the antibody-antigen reaction varied
inversely with ionic strength. In particular, the association
rate constant was negatively affected by salt concentra-
tion, suggesting that electrostatic forces contributed to
antigen binding. Also pH affected the interaction with
affinity increasing with decreasing pH. However, the
sequences of the phagotopes do not support a dominant
role for ionic interactions in the epitope-paratope reac-
tion. It seems more likely that these effects are due to addi-
tional interactions away from the epitope-paratope
region. Interestingly, when mAb 3C4 was allowed to bind
to immobilized holoTC, the pH and ionic strength effects
largely disappeared, neither kon nor koff were significantly
affected. With respect to koff, this may be explained by the
difference in valency of binding. HoloTC is bound mono-
valently to mAb3C4 whereas mAb3C4 is bound biva-
Calibration curves for the three assay formats of Fig. 3, and a comparison of prototype assay with HoloTC RIAFigu e 4
Calibration curves for the three assay formats of Fig. 3, and a comparison of prototype assay with HoloTC 
RIA. (A) Calibration curve for prototype assay using mAb 3C4 as capture ligand (format A). (B) Comparison of the prototype 
assay and HoloTC RIA for 15 serum samples ranging from 14 to 139 pmol/L as determined by HoloTC RIA. (C) Calibration 
curve for assay using mAb 3C4 as the detecting ligand (format B). (D) Calibration curve of assay for cobalamin TC saturation 
(format C).Page 9 of 11
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will be released at a lower rate. However, it is possible that
immobilized holoTC can become more refractory to a
conformational change induced by pH and ionic strength
alterations. An antibody to a discontinuous epitope
would be more susceptible to changes in the antigen pres-
entation than an antibody with a continuous epitope,
such as mAbs 3–11 and 3–9.
The main objective of this study was to investigate the
possibility to develop direct assays for holoTC that are
adaptable to the larger clinical instruments. The existing
commercially available assay for holoTC, HoloTC RIA, is
a manual radioassay, which is based on the principle that
all TC in a sample is captured and separated whereupon
Cbl is released and measured in a competitive radioassay
[11]. Although being robust and sensitive, it does not lend
itself easily to automation, and thus cannot be used to
measure the many hundreds to thousands of samples sent
to the clinical laboratory. In addition it requires 400 µL of
sample. The identification of a mAb with a high specificity
for holoTC has provided a unique tool to develop an assay
that is specific, direct, and can be easily automated. We
here give proof of concept for three different assay for-
mats; one using mAb 3C4 as the capture reagent, one as
the detecting reagent and one measuring the saturation
ratio (Fig. 3). The saturation ratio (holoTC:total TC) may
be a better representative of cobalamin concentration [9]
and has the advantage of being independent of sample
volume. Because of the dependency of the antigen-anti-
body interaction on ionic strength when the antigen is in
the free phase, as discussed above, an assay format using
the holoTC specific antibody as the detecting reagent
would be best suited for further development. However,
because of non-specific binding of the holoTC specific
antibody to the elisa plate surface, the signal-to-noise
ratio was superior with a format using the holoTC specific
antibody as the capture reagent. Therefore we chose to
develop the first format and compare this to the commer-
cial assay using 15 different serum samples. The correla-
tion was good with Y = 0.78X-0.40 and r = 0.96 (Fig. 4B).
The slope differed from unity, but that may be explained
by the use of different calibrators in the two assays. In
HoloTC RIA was used the calibrators supplied with the kit
that are made up of recombinant holoTC. In the proto-
type assay we used serum-based calibrators, which as yet
have not been normalized against the recombinant cali-
brators.
Conclusion
We have identified a monoclonal antibody with a unique
specificity for the holo-form of human transcobalamin.
The specificity arises from conformational changes occur-
ring in transcobalamin upon binding of cobalamin and
cobalamin as such is not part of the epitope. Using this
antibody we have successfully developed a prototype
assay that allows the simple and direct quantification of
holoTC in human blood. We are currently continuing the
development of this prototype assay into an automatic
holoTC test for routine use.
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